Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.54 |
| ▸ | CTSK | P43235 | 9/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022798 | 0.89 | CTSS (0.52) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5059307 | 0.82 | CTSL (0.47) | CTSSCTSBCTSLPSEN1PSEN2 | |
| SCHEMBL1023417 | 0.80 | CTSS (0.54) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1021956 | 0.79 | CTSS (0.55) | CTSSCTSKCTSBCTSLPSEN1 | |
| SCHEMBL1021946 | 0.79 | CTSS (0.51) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2265883 | 0.78 | SYK (0.54) | CTSSCTSKCTSBCTSLSYK | |
| SCHEMBL2265891 | 0.78 | SYK (0.54) | CTSSCTSKCTSBCTSLSYK | |
| SCHEMBL1024058 | 0.78 | SYK (0.45) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1022568 | 0.78 | CTSS (0.47) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1022989 | 0.77 | CTSS (0.54) | CTSSCTSKCTSBCTSLPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | CTSS 107/4885CTSK 127/4885CTSB 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.